We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 13, 2020

Efficacy and Safety of Setmelanotide in Individuals With Severe Obesity Due to LEPR or POMC Deficiency

The Lancet Diabetes & Endocrinology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Efficacy and Safety of Setmelanotide, an MC4R Agonist, in Individuals With Severe Obesity Due to LEPR or POMC Deficiency: Single-Arm, Open-Label, Multicentre, Phase 3 Trials
Lancet Diabetes Endocrinol 2020 Oct 30;[EPub Ahead of Print], K Clément, E van den Akker, J Argente, A Bahm, WK Chung, H Connors, K De Waele, IS Farooqi, J Gonneau-Lejeune, G Gordon, K Kohlsdorf, C Poitou, L Puder, J Swain, M Stewart, G Yuan, M Wabitsch, P Kühnen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading